Only 20% of lung cancer cases caught by x-rays
the ONA take:
According to a Norwegian study, ultralow-dose computerized tomography (CT) scans catch 89% of lung cancer cases, while x-ray examinations only catch 18% of cases. In the study, researchers asked radiologists at Oslo University Hospital in Oslo, Norway, to examine x-ray and CT scan images and to identify possible diseases in the chest.
In Norway, over 1 million people undergo x-ray imaging and most patients with lung cancer are first diagnosed by using x-ray examinations. Despite the increased accuracy with CT imaging, clinicians have been hesitant to use this method as first-line screening because of the increased radiation. Until modern ultralow-dose CT imaging, the radiation dose has been 100 times greater than x-ray imaging or equal to 5 years of natural background radiation.
If an examination with x-ray is negative, substantial time may pass before a patient is recommended for CT imaging. That time may be enough for the lung cancer to grow, spread, and become deadly. According to the Centers for Disease Control and Prevention, lung cancer is deadlier than any other type of cancer for both males and females in the United States. Unfortunately, CT scans are substantially more expensive than x-ray examinations.
With modern ultralow-dose CT, the radiologists hit the bull's eye on lung cancer 90% of the time.
Each year, 2800 Norwegians develop the dreaded disease. Their prognosis is unpromising: six out of seven die within five years. What is especially unfortunate about lung cancer is that the tumour has ample space to grow.
It can thus grow for a long time before being detected. Most patients have their first diagnosis made by x-ray imaging. Each year, Oslo University Hospital takes 30 000 chest x-rays. Nationwide, this number exceeds one million.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|